PORTFOLIO

The Mid-Atlantic Angel Group Funds I & II, LP (MAG I & II)

Biopticon Corporation is a developer, manufacturer, and marketer of next-generation measurement and data management systems for preclinical animal studies. Biopticon's proprietary solutions give researchers performing oncology preclinical animal studies, the ability to accelerate the drug development process by improving the performance, throughput, cost effectiveness, and flexibility of their preclinical animal studies

Carnegie Speech Company is the premier developer of software for assessing and teaching spoken language skills. Using state-of-the-art speech recognition and artificial intelligence technologies licensed from Carnegie Mellon University, Carnegie Speech enables cost-effective, scalable and personalized spoken-language instruction that maximizes training effectiveness and minimizes training time. With years of linguistic research, world-class technology and language tutoring expertise, Carnegie Speech provides language training products to a diverse and global clientele. Visit www.carnegiespeech.com.

NanoPack Inc. is a materials science company formed in 2004, that develops and markets cost-effective, environmentally-friendly materials for the packaging industry, particularly for food-packaging applications where protection of contents from oxygen is important for shelf life. The primary products manufactured include barrier coatings that are printed onto flexible films and the printed barrier films themselves.

MD - detect-ready.com - Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of "sample-to-answer" Detect-Ready™ molecular diagnostic tests for the rapid detection of infectious diseases. The company is preparing to launch its first product, the Detect-Ready assay for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA), a growing problem among hospitals and other health facilities around the globe.

MDI's mission is to become a leading molecular diagnostics company leveraging its novel technologies to commercialize products for the accurate, rapid and cost-effective detection of infectious diseases. MDI's Detect-Ready MRSA assay is a real-time PCR test designed to provide increased accuracy, faster time to results and more efficient utilization of hospital resources than other MRSA diagnostic products. MDI is also developing Detect-Ready assays to test for the presence of other microbial agents, including C.difficile, sexually transmitted diseases (STDs) and foodborne pathogens. The company's products are based on novel patent-pending technologies that provide greater accuracy and speed while simplifying assay storage and use.

MDI was founded in 2007 and is headquartered in Wayne, PA. It has research operations and an ISO 9001 and 13485 certified manufacturing facility in Israel.

Headquartered in Malvern, Pennsylvania, Protez Pharmaceuticals is engaged in the discovery and development of new antibiotics for difficult-to-treat infections. Its focus is on highly differentiated intravenous and oral small molecule antibiotics to address increasing bacterial resistant and chronic or recurrent infections. Protez was acquired in June 2008 and is a stand alone subsidiary of Novartis.

TL - ticketleap.com - Chris Stanchak founded TicketLeap in 2003 to bring professional-grade ticketing to events too small to get the attention of the big ticketing companies. He saw an opportunity to put cutting-edge ticketing in the hands of every event organizer, whether they were selling 100 tickets or 100,000 tickets. Today, TicketLeap is the fastest growing ticketing company in the U.S. for small-to-midsize events, helping over 8,000 event organizers increase their sales and simplify their ticketing.

Yaupon Therapeutics is a privately held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The company has three products in development, with one compound in pivotal studies, one compound in phase 2 and additional compounds positioned to enter clinical development in the near future. The company's business strategy is to build a highly capital efficient organization that leverages the NIH competitive grant system to offset research expenses and to validate its technology. The model emphasizes strong academic collaborations that lead to the licensing and development of unique products with proof of principle and millions of academic research dollars behind them.